- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02861677
Impact of Clinical Pharmacy Service on Patient Care and Cost Saving (TGPIONEER)
Background: Pharmacists have been proven to improve patient outcomes, medication adherence, glycemic control, reduce blood pressure, low-density lipoprotein, health care costs and length of hospital stay, and enhance quality of life.
Objective: to measure the impact of clinical pharmacy service on patient care and cost saving of patients at inpatient wards and ambulatory care clinics of Jimma University Specialized Hospital.
Methods: single center Randomized Controlled Trial will be conducted. Participants will be assigned to either pharmacy professionals' intervention group or non-intervention (control) group based on computer generated random number. The study will be done from July 26 to September 15, 2016. The total sample size is calculated with Open Epi online sample size calculator with 95% CI and 80% power. The total sample size is found to be 146 for inpatients and 473 for outpatients. Linear regression, student's t-test, logistic regression and chi-square test will be used for statistical analysis. Variables with p<0.05 will be considered statistically significant.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Many studies have shown the positive impact of clinical pharmacy service on clinical, economic and humanistic outcomes. This type of service may be highly important in saving lives, improving patient outcomes, and decreasing treatment costs particularly in resource-limited settings like Ethiopia with a double burden of communicable and non-communicable diseases which need medication therapy. Though patients may experience a number of problems related to drug therapy, no study is conducted in Ethiopia to show the impact of clinical pharmacy service in alleviating such treatment related problems.
Therefore, this study aims to answer the following research questions.
impact of clinical pharmacy service in improving patient outcome and reducing cost of treatment of chronic illness patients
impact of clinical pharmacy service in improving patient outcome and reducing cost of treatment of hospitalized patients
Study site location and participants: this randomized controlled trial will be conducted at Jimma University Specialized Hospital, Southwest Ethiopia.
Sample size calculation
The sample size for inpatients is calculated using the Open Epi online sample size calculator software with the following assumptions:
With 80% power and significance level of 0.05 with a 95% confidence interval. Two tailed test and a 1:1 ratio between intervention group and control group. The investigators used the prevalence of drug related problem (primary outcome) to be 52% from previous reports in Ethiopia.
The effect size is considered to be 1.5
Through calculation, the final sample size in each arm is 61 and considering a 20% contingency for loss to follow up, 73 participants are needed in each group. Therefore, the total sample size is 146.
For ambulatory patients, sample size is calculated using the prevalence of the three types of drug related problems (indication, safety, and effectiveness) from previous studies. The prevalence of effectiveness related drug related problem was reported to be 14%. The effect size is determined to be 1.4 and all other parameters are considered similar to the above. Through calculation, 215 patients are needed in each group. Considering a 10% loss for follow up, the total sample size is 473 in the two groups.
Randomization and concealing allocation
Randomization will be completed by Statistical Package for the Social Science version 21 generated algorithm. Treating assignments kept in sealed opaque envelopes with only number labeled will be opened after patients give their informed consents. The assigned research assistant will distribute envelopes and record patients in each group enrollment and patient assignment.
Blinding: research assistants of the trial who are responsible for outcome recording will be blinded to treatment assignment.
Intervention:
Pharmacy Intervention group
For Hospitalized Patients:
Four full timer pharmacists trained on clinical pharmacy (ward Pharmacists) will be assigned to 8-15 patients each at medical ward to provide clinical pharmacy service.
Two full timer postgraduate year two clinical pharmacy students will be assigned to medical ward A Male and medical ward B female.
Two clinical pharmacists from school of pharmacy will also be assigned to each ward.
For Ambulatory Patients;
Two post graduate year II clinical pharmacy students will be assigned to outpatient department of ambulatory care clinic.
The assigned pharmacy professionals will sit with the physician and make therapeutic decisions in consultation with the physician, develop therapeutic plan and give patient education and document into the documentation form.
Control Group
Patients in the control group will get the standard care by physicians and nurses.
Measurement
Primary outcomes
Interventions by Pharmacy professionals
For hospitalized patients, all interventions made by pharmacy professionals will be documented on pharmacy professional activity documentation forms. Data collectors will abstract all the relevant data from the document. The data that will be abstracted by data collectors are:
Identified drug therapy problems and interventions made to resolve drug therapy problems.
Suggestions on prevention and avoidance of medication errors.
Cost of medicines and pharmaceuticals.
Cost of hospitalization including cost of laboratory investigations.
Patient educations given during hospital stay and at discharge for hospitalized patients.
Recommendations made for laboratory investigation and treatment monitoring done.
Patient education at hospital for ambulatory patients.
Secondary outcomes
Length of hospital stay
In hospital mortality
Patient knowledge about the drug at discharge
Inpatient satisfaction with the health care service provided
For ambulatory patients,
Primary outcome
Identified drug therapy problems and interventions made to resolve drug therapy problems.
Cost of medicines
Secondary outcomes
Patient knowledge about the prescribed medicines
Statistical analysis: Statistical software Statistical Package for the Social Science 21 will be used for analysis. Variables with p value<0.05 will be considered statistically significant.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Tigestu Desse, MSc
- Telefonnummer: +251923533706
- E-Mail: tgfrekidan16@gmail.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥18 years old,
- Patients admitted to internal medicine ward,
Ambulatory patients with the following non-communicable diseases:
- diabetes mellitus,
- hypertension,
- heart failure,
- ischemic heart disease,
- rheumatoid heart diseases,
- chronic kidney disease,
- venous thromboembolism,
- asthma, chronic obstructive pulmonary disease, and epilepsy who have been on treatment for at least three months.
Exclusion Criteria:
- Hospitalized medical inpatients with the following conditions.
Drop outs:
- Patients leaving against medical advice, die and abscond within 72 hours of admission.
- Patients not willing to participate.
- Patients who may be transferred from intensive care unit to internal medicine ward.
- Patients who may be transferred from other wards to internal medicine ward.
- Patients admitted with stroke.
Chronic illness ambulatory patients with the following conditions:
- Patients not willing to participate.
- Women with gestational diabetes.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Kein Eingriff: Control group
The control group will receive the usual medical care by physicians and nurses
|
|
Experimental: Intervention group
the intervention group will receive clinical pharmacy services
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The number of drug therapy problems
Zeitfenster: through study completion, an average of 8 weeks
|
through study completion, an average of 8 weeks
|
The number of medication errors
Zeitfenster: through study completion, an average of 8 weeks
|
through study completion, an average of 8 weeks
|
Cost of medicines
Zeitfenster: through study completion, an average of 8 weeks
|
through study completion, an average of 8 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Length of hospital stay
Zeitfenster: through study completion, an average of 8 weeks
|
through study completion, an average of 8 weeks
|
In hospital mortality
Zeitfenster: through study completion, an average of 8 weeks
|
through study completion, an average of 8 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- Rpge/502/2016
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Health Care Improvement
-
University of Dublin, Trinity CollegeUnbekanntBrain Health Elite-Athleten im Ruhestand
-
Universidad Francisco MarroquínEcole Polytechnique, France; The SHM Foundation, UKAbgeschlossenExklusives Stillen | Koproduktion von Health in Communities
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAktiv, nicht rekrutierendPräventive Gesundheitsdienste (PREV HEALTH SERV)Vereinigte Staaten
-
KTO Karatay UniversityAbgeschlossenGesundes Lebensstilverhalten | E-Health-KompetenzTruthahn
-
South West Yorkshire Partnership NHS Foundation...UnbekanntGründe für die Inhaftierung nach dem Mental Health Act 1983Vereinigtes Königreich
-
Yusuf Ziya AarslanIrem HüzmeliNoch keine RekrutierungHealth Care Acceptor Gesundheitswissen, Einstellungen, Patientenbeteiligung üben
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenImmigrant Caregiver Health Care Navigation für KinderVereinigte Staaten
-
Kliniek ViaSanaSt. Anna Ziekenhuis, Geldrop, NetherlandsAbgeschlossenSchmerzen | Opioidgebrauch | Totaler Kniegelenkersatz | E-Health-AppNiederlande
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesRekrutierungHämatopathologie-geeignet oder CAR-t-ZellbehandlungFrankreich
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutierungKomplikationen der CAR-T-TherapieItalien
Klinische Studien zur pharmaceutical care
-
Shuqun ChengUnbekanntHepatozelluläres KarzinomChina
-
TABREJ MUJAWARAbgeschlossen
-
Southeast University, ChinaChinese Academy of SciencesAbgeschlossenSepsis | Septischer Schock | Ambulant erworbene PneumonieChina
-
The Third Xiangya Hospital of Central South UniversityNoch keine RekrutierungCharcot-Marie-Tooth-Krankheit (CMT)
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekrutierungPlasmazell-Leukämie | Rezidiviertes/refraktäres multiples MyelomChina
-
yongjun wangAbgeschlossenIschämischer SchlaganfallChina
-
Nexcella Inc.Noch keine RekrutierungLeichtketten (AL)-AmyloidoseVereinigte Staaten
-
Second Affiliated Hospital, School of Medicine,...RekrutierungRezidiviertes und refraktäres B-Zell-LymphomChina
-
Second Affiliated Hospital, School of Medicine,...Rekrutierung
-
Hebei Senlang Biotechnology Inc., Ltd.RekrutierungLymphom | Multiples Myelom | Akute lymphatische LeukämieChina